Latest Flerie News & Updates

See the latest news and media coverage for Flerie. We track all announcements, press releases, and industry mentions in real time, all in one place.

Flerie

Active long-term life science investor

flerie.com

Headquarters: Stockholm, Sweden
Founded year: 2011
Company type: Private company
Number of employees: 10–16
Industry: Investment Holding Companies

Last updated October 23

Latest news about Flerie

In short: Flerie advanced Biosergen merger as Q3 NAV fell on Empros write-down

Company announcements

October 14 Flerie

Flerie publishes interim report for January-September 2026

The result amounted to -281 mkr. The portfolio value fell by 8.7 percent to 2.7 billion kronor after a write-down in Empros Pharma.

October 7 Flerie

Flerie reports net asset value of SEK 3,113 million for September 2026

The monthly return on NAV per share was -6.8%, with the portfolio valued at SEK 2,065 million in product development and SEK 661 million in commercial growth.

September 30 Flerie

Flerie writes down Empros Pharma holding value by SEK 2.66 per share

Limited prospect of external funding or divestment drives the write-down due to financing difficulties for Phase 3 trials amidst GLP-1 competition.

September 29 Flerie

Flerie's portfolio company Egetis gets FDA approval for EMCITATE in the USA

The drug treats MCT8 deficiency and grants a priority review voucher. Commercial availability is expected within 8-10 weeks starting from late September.

Media coverage

October 23 Zone Bourse

Flerie AB (publ) (OM:FLERIE) has completed the acquisition of Biosergen AB (publ) (OM:BIOSGN) from Östersjöstiftelsen, Ribbskottet AB and other parties for ...

On June 25, 2026, Flerie AB agreed to acquire Biosergen AB from Östersjöstiftelsen, Ribbskottet AB and other parties for 1.5 million SEK. In...

October 14 Zone Bourse

Flerie AB (publ) publishes its financial results for the third quarter and the nine months ended September 30, 2026

Flerie AB has published its financial results for the third quarter and the nine months ended September 30, 2026. In the third quarter, the company...

October 14 Dagens industri

Net asset value falls due to write-downs

Investment company Flerie reports a net asset value for Q3 2026 of SEK 35.91 per share, weighed down by accounting write-downs.

September 30 Finanznachrichten

Flerie AB: Flerie writes down net asset value of portfolio company Empros Pharma

Flerie AB (publ) has taken the decison to write down the value of its holding in the portfolio company Empros Pharma. The decision is based...

Never miss news about Flerie

Track Flerie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Flerie competitors & trending companies

Browse news for competitors to Flerie and other trending companies.